We have created two infographics to help illustrate the full medicines development pathway:
Some of the key areas we work on with our member companies, together with a brief description of the work we do, are detailed in the following sections:
On average, it takes over 12 years and costs over £1 billion to develop new medicines. Can't believe it? Take a look at our 'time to flourish' infographic.
The overarching aim of our work in this area is to catalyse a transformation in innovation within the UK-based life science arena, improving the productivity of the research and development process and reinforcing the UK’s global role and influence
Early research and development relates to the activities of chemists, biologists and pharmacologists who develop and test new active substances in the laboratory, through to the translation of these new therapies to early clinical research in humans.
eHealth data refers to any data that has a heath related aspect and is stored and captured electronically.
We work with members and key partners to enhance the clinical research environment in the UK, striving to be competitive within Europe for initiating and completing valuable research.
Regulatory affairs is the function within our industry that ensures companies comply with the regulations and laws that apply to the pharmaceutical industry.
No medicine is 100% safe. Drug safety (also known as pharmacovigilance), is the science of detection, assessment, understanding and prevention of side effects which allows us to understand more about the risks and benefits of a medicine.
The UK biopharmaceutical industry has a long and proud record of high quality, reliable manufacturing of medicinal products The UK medicines industry is one of our leading manufacturing sectors, with exports worth £24 billion and generating a trade surplus of £4.9 billion in 2012.
This tool was developed for the ABPI by the Carbon Trust with contributions from the ABPI, AstraZeneca, GlaxoSmithKline, Janssen (J&J), Eli Lilly, and Pfizer.